Reparixin (Repertaxin)

Catalog No.S8640 Synonyms: DF 1681Y

For research use only.

Reparixin (Repertaxin, DF 1681Y) is a potent and specific inhibitor of CXCR1 with IC50 of 1 nM. Reparixin (Repertaxin) inhibits PMN migration induced by CXCL8 (IC50 = 1 nM) and rodent PMN chemotaxis induced by CXCL1 and CXCL2. Repertaxin inhibits the response of human PMN to CXCL1, which interacts with CXCR2 (IC50 = 400 nM).

Reparixin (Repertaxin) Chemical Structure

CAS No. 266359-83-5

Selleck's Reparixin (Repertaxin) has been cited by 10 Publications

Purity & Quality Control

Choose Selective CXCR Inhibitors

Other CXCR Products

Biological Activity

Description Reparixin (Repertaxin, DF 1681Y) is a potent and specific inhibitor of CXCR1 with IC50 of 1 nM. Reparixin (Repertaxin) inhibits PMN migration induced by CXCL8 (IC50 = 1 nM) and rodent PMN chemotaxis induced by CXCL1 and CXCL2. Repertaxin inhibits the response of human PMN to CXCL1, which interacts with CXCR2 (IC50 = 400 nM).
CXCR1 [3]
(Cell-free assay)
CXCL8 [3]
(Cell-free assay)
CXCR2 [3]
(Cell-free assay)
1 nM 1 nM 400 nM
In vitro

Reparixin is a non-competitive allosteric blocker of CXCR1 and CXCR2 receptor activation, which inhibits intracellular signal pathways without affecting receptor bindings. Reparixin potently and selectively inhibits a wide range of biological activities that are induced by CXCL8 such as leukocytes recruitment and functional inflammatory reactions. However, reparixin does not affect CXCR1/CXCR2 activation induced by other chemotactic factors, C5a, fMLP, CXCL12 or several other agonists of GPCRs. Reparixin can regulate the production of angiotensin II receptors, which may influence Ang II-induced hypertension[1]. Reparixin specifically blocks CXCR1/2-mediated mouse and human neutrophil migration in vitro without affecting other receptors. Reparixin inhibits CXCL8-induced neutrophil activation through human CXCR1 and human CXCR2 and blocks phosphorylation of downstream signalling molecules. Reparixin prevents the increase of intracellular free calcium, elastase release and production of reactive oxygen intermediates, but leaves phagocytosis of Escherichia coli bacteria unaffected[2].

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
polymorphonuclear cells MYTGeY5kfGmxbjDhd5NigQ>? MkXDTY5pcWKrdHnvckBw\iCFWFPMPE1qdmS3Y3XkJINp\W2xdHH4bZMhcW5iaIXtZY4heG:ueX3vdpBpd263Y3zlZZIh[2WubIOsJGlEPTB;MD6wNFU{|ryP M13Vc|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF3OUe0OVg2Lz5zNUm3OFU5PTxxYU6=
L1.2 MULGeY5kfGmxbjDhd5NigQ>? M1zl[GlvcGmkaYTpc44hd2ZiQ2jDUFgucW6mdXPl[EBk\WyuIH3p[5JifGmxbjDpckBNOS5{IHPlcIx{KGW6cILld5NqdmdiQ2jDVlEh[nliY3jlcY91[XirczDhd5NigSxiSVO1NF0xNjByNUdOwG0> M3XIfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5Nk[1PFg6Lz5zN{[2OVg5QTxxYU6=
L1.2 M1[2b2Z2dmO2aX;uJIF{e2G7 MmnYTY5pcWKrdHnvckBw\iCFWFPMPE1qdmS3Y3XkJINmdGxibXnndoF1cW:wIHnuJGwyNjJiY3XscJMh\XiycnXzd4lv\yCLbHW0N3ZidCCFWFPSNUBufXSjboSgZpkh[2inbX;0ZZhqeyCjc4PhfUwhUUN3ME2wMlA5|ryP NFrONIU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{[2OVg5QSd-MUe2OlU5QDl:L3G+
L1.2 M2\kNGZ2dmO2aX;uJIF{e2G7 NIXIboh2eCC2bzCxNFAxKG6P MlS2TY5pcWKrdHnvckBw\iCFWFPMPE1qdmS3Y3XkJINmdGxibXnndoF1cW:wIHnuJGwyNjJiY3XscJMh\XiycnXzd4lv\yC5aXzkJJR6eGViQ2jDVlEh[XRidYCgeI8hOTByMDDuUUBjgSClaHXtc5RigGm|IHHzd4F6 MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzZ4NUi4PUc,OTd4NkW4PFk9N2F-
Methods Test Index PMID
Western blot IL-8 / STAT3 / p-STAT3 / AKT / p-AKT ; CXCR1 / CACR2 / Bcl-2 / Bax / Cyclin D1 / VEGF / MMP-2 / MMP-9 / TIMP-2 / E-cadherin / p-ERK / ERK 30397072 26847910
Immunofluorescence p-FAK / p-AKT / FOXO3A 20051626
In vivo

Reparixin, an inhibitor of CXCL8 receptor CXCR1 and CXCR2 activation, attenuates inflammatory responses in various injury models. Reparixin effectively decreases systolic blood pressure and increases the blood flow. The thoracic aorta wall thickness is significantly decreased in SHR-R (the reparixin-treated group) compared to SHR-N (normal saline-treated SHR)[1]. (SHR: Spontaneously hypertensive rats)

Protocol (from reference)

Cell Research:


  • Cell lines: HUVECs
  • Concentrations: 1 μM
  • Incubation Time: 30 min
  • Method:

    HUVECs are pretreated without or with reparixin (1 μM) for 30 min. Cells were then treated with or without Ang II (100 nmol/l) or CXCL8 (100 ng/ml) for 2 h. After total RNA is isolated, real-time PCR was performed.

Animal Research:


  • Animal Models: SHR rats
  • Dosages: 5 mg/kg
  • Administration: s.c.

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 283.39


CAS No. 266359-83-5
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC(C)CC1=CC=C(C=C1)C(C)C(=O)NS(=O)(=O)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT01861054 Terminated Drug: Reparixin Breast Cancer Dompé Farmaceutici S.p.A February 2013 Phase 2

(data from, updated on 2022-08-01)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.

Frequently Asked Questions

Question 1:
Do you have the information of the half life time of reparixin Catalog No.S8640 in rats?

The following paper indicated the half-life of this compound in rats is 0.5h (

Tags: buy Reparixin (Repertaxin) | Reparixin (Repertaxin) supplier | purchase Reparixin (Repertaxin) | Reparixin (Repertaxin) cost | Reparixin (Repertaxin) manufacturer | order Reparixin (Repertaxin) | Reparixin (Repertaxin) distributor